Sanofi-Aventis Enters Diabetes Pact With AgaMatrix For Blood Glucose Monitors
This article was originally published in The Pink Sheet Daily
Executive Summary
AgaMatrix will develop a portfolio of blood glucose monitors exclusively for Sanofi-Aventis, which can now market an array of diabetes products.
You may also be interested in...
Biosimilar Insulin Worth The Effort? For Some, Maybe
With most eyes fixed on the imminent arrival of biosimilar antibodies – billed as the most valuable copy-cat biologics, given originators' high prices – it may be easy to overlook the potential of first-generation biosimilars such as insulin.
Biosimilar Insulin Worth The Effort? For Some, Maybe
With most eyes fixed on the imminent arrival of biosimilar antibodies – billed as the most valuable copy-cat biologics, given originators' high prices – it may be easy to overlook the potential of first-generation biosimilars such as insulin.
Under Pressure: Sanofi's Strategy Will Be Tested By Generic Lovenox Approval
Ahead of the big pharma's earnings call July 29, Sanofi-Aventis is under renewed pressure with Momenta and partner Sandoz promising a swift launch of their newly approved generic version of Lovenox.